From Industry to “TechBio”: Our Vision for the Healthcare of Tomorrow

In a recent conversation with Dan Sherrard-Smith for the Founder’s Story podcast, Hervé de Maillard reflected on the core mission of Maison MGA: our obsession with putting complex engineering at the service of life.

It all started thirty years ago in China. Between 1994 and 1999, Hervé witnessed firsthand a culture defined by immediate execution and long-term vision. “Everything happening in China today was already written in their plan three decades ago,” he points out. This ability to decide quickly while looking far ahead is exactly what we strive to bring to our engineering projects today.

After building factories across five continents, one thing became clear to us. While robotics revolutionized the automotive industry, it has only begun to scratch the surface of what is possible in the life sciences. This is the heart of what we call “TechBio.” Unlike traditional biotech, which focuses on mass production, TechBio uses technology to scale down to the individual. We are moving away from giant vats and toward personalized medicine: a unique treatment, tailor-made for a single patient.

In practical terms, this requires instruments of surgical precision. Hervé often points to two examples close to our hearts: precision diagnostics, capable of isolating DNA traces in nano-droplets to adjust cancer treatments in real-time, and 3D cell encapsulation, which is set to secure the cell therapies of tomorrow.

The horizon we have set is ambitious. We are convinced that by 2050, nearly all known diseases will be treatable. However, this technological acceleration carries an immense ethical responsibility. For us, technology must remain a tool,a “pen” used to write a new chapter in healthcare, rather than an end in itself. At Maison MGA, we move forward with a simple conviction: innovation only matters if it respects life and humanity.

This is the future, both technological and profoundly committed, that we are building every day.